Reuters logo
BRIEF-Adocia initiates study comparing BioChaperone Lispro U100 with Fiasp and Novolog
June 1, 2017 / 7:00 PM / 4 months ago

BRIEF-Adocia initiates study comparing BioChaperone Lispro U100 with Fiasp and Novolog

June 1 (Reuters) - ADOCIA SA:

* ADOCIA INITIATES A STUDY COMPARING ULTRA-RAPID INSULIN BIOCHAPERONE LISPRO U100 WITH FIASP AND NOVOLOG ADMINISTERED WITH AN INSULIN PUMP

* ‍TOPLINE RESULTS OF TRIAL ARE EXPECTED BY YEAR END​

* FIRST CLINICAL TRIAL TO COMPARE TWO “ULTRA-RAPID” INSULIN FORMULATIONS HEAD-TO-HEAD IN PEOPLE WITH TYPE 1 DIABETES

* ‍STUDY WILL BE SPONSORED BY ADOCIA AND PERFORMED BY PROFIL NEUSS IN GERMANY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below